Merck & Caris Discovery Forge $1.4B AI-Driven ADC Collaboration

Recently, AI TechBio's Caris Discovery announced a multi-year collaboration with MSD to develop transformative ADC therapies.

According to the terms of the agreement, MSDWill provide Caris with upfront payment and research funding. In addition, Caris will be eligible for milestone payments based on discovery, development, regulatory, and sales, along with tiered royalties, potentially totaling up to$1.4 billion

GermanyMerck KGaA of Darmstadt to Receive Exclusive Global License for Development, Manufacturing, and Commercialization of ADC Therapies for Selected Targets.

Caris Life Sciences is an AI TechBio company and a precision medicine company dedicated to actively developing and delivering innovative solutions by leveraging molecular science and artificial intelligence to revolutionize healthcare and improve the human condition.

By applying comprehensive molecular analysis (whole-exome and whole-transcriptome sequencing) along with advanced artificial intelligence and machine learning algorithms, Caris has developed the large-scale, multi-modal databases and computational capabilities necessary to analyze and uncover the molecular complexity of diseases.

Caris Discovery leverages the scale of Caris' core molecular profiling business to uncover novel druggable targets that would be unattainable through more conventional methods.

By integrating its proprietary ADAPT Biotargeting platform, a synchronized patient tissue repository, a suite of advanced artificial intelligence and machine learning capabilities, and a 59,000-square-foot dedicated discovery research laboratory, Caris Discovery aims to identify and validate novel therapeutic targets that can be leveraged by its biopharmaceutical partners to develop the next generation of oncology treatments.

Global Head of Oncology Research, Healthcare Business Unit, MSDPaul Lyne"We are committed to addressing the significant unmet needs across multiple cancer types." "By closely collaborating with Caris and leveraging their unique discovery platform, we are complementing our internal ADC capabilities to develop novel, first-in-class ADCs, ultimately enhancing our potential to expand our oncology portfolio."

Milan Radovich, Ph.D., Chief Scientific Officer and Senior Vice President of Caris, stated, "Caris Discovery is identifying novel unexplored targets for patient populations that currently lack precision treatment options." "We are proud to collaborate closely with Merck Darmstadt, Germany, to bring new therapeutic options to cancer patients."